Prolonged treatment with transcutaneous electrical nerve stimulation (TENS) modulates neuro-gastric motility and plasma levels of vasoactive intestinal peptide (VIP), motilin and interleukin-6 (IL-6) in systemic sclerosis

Clinical and Experimental Rheumatology

Volumn 31, Issue SUPPL.76, 2013, Pages

  McNearney, Terry A ^a   Sallam, Hanaa S ^a   Hunnicutt, Sonya E ^a   Doshi, Dipti ^a   Chen, Jiande D Z ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Gastric dysmotility; Perceived functioning; Scleroderma; SF 36

Indexed keywords

IL6 PROTEIN, HUMAN; INTERLEUKIN 6; MOTILIN; VASOACTIVE INTESTINAL POLYPEPTIDE;

ARTICLE; BLOOD; CLINICAL TRIAL; ELECTROCARDIOGRAPHY; ELECTROMYOGRAPHY; FEMALE; GASTROINTESTINAL MOTILITY; HEALTH STATUS; HEART RATE; HUMAN; INNERVATION; MALE; METHODOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; PATIENT SATISFACTION; PHYSIOLOGY; STOMACH; STOMACH PARESIS; SYSTEMIC SCLEROSIS; TRANSCUTANEOUS NERVE STIMULATION; TREATMENT OUTCOME;

ELECTROCARDIOGRAPHY; ELECTROMYOGRAPHY; FEMALE; GASTROINTESTINAL MOTILITY; GASTROPARESIS; HEALTH STATUS; HEART RATE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; MOTILIN; PATIENT SATISFACTION; SCLERODERMA, SYSTEMIC; STOMACH; TRANSCUTANEOUS ELECTRIC NERVE STIMULATION; TREATMENT OUTCOME; VASOACTIVE INTESTINAL PEPTIDE;

EID: 84883806077     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. CLEMENTS PJ: 2003 Systemic Sclerosis, Williams and Wilkins, Baltimore, MD
2. SJöGREN RW: Gastrointestinal motility disorders in scleroderma. Arthritis Rheum 1994; 37: 1265-82.
3. ABU-SHAKRA M, GUILLEMIN F, LEE P: Gastrointestinal manifestations of systemic sclerosis. Semin Arthritis Rheum 1994; 24: 29-39.
4. SALLAM H, McNEARNEY T, CHEN J: Systematic review: pathophysiology and management of gastrointestinal dysmotility in systemic sclerosis (scleroderma). Aliment Pharmacol Ther 2006; 23: 691-712.
5. PFAFFENBACH B, ADAMEK RJ, HAGEMANN D, WEGENER M: Gastric myoelectrical activity and gastric emptying in patients with progressive systemic sclerosis. Am J Gastroenterol 1996; 91: 411-3.
6. MARYCZ T, MUEHLDORFER SM, GRUSCHWITZ MS et al.: Gastric involvement in progressive systemic sclerosis: electrogastrographic and sonographic findings. Eur J Gastroenterol Hepatol 1999; 11: 1151-6.
7. HOCKE M, SEIDEL T, SPROTT H, OELZNER P, EITNER K, BOSSECKERT H: Ambulatory electrogastrography in patients with sclerodermia, delayed gastric emptying, dyspepsia, and irritable bowel syndrome. Is there any clinical relevance? Eur J Int Med 2001; 12: 366-71.
8. MARIE I, LEVESQUE H, DUCROTTE P et al.: Gastric involvement in systemic sclerosis: a prospective study. Am J Gastroenterol 2001; 96: 77-83.
9. McNEARNEY T, LIN X, SHRESTHA J, LISSE J, CHEN JD: Characterization of gastric myoelectrical rhythms in patients with systemic sclerosis using multichannel surface electrogastrography. Dig Dis Sci 2002; 47: 690-8.
10. WOLLASTON DE, XIAOHONG X, TOKUMARA, O. CHEN JDZ, McNEARNEY TA: Systemic Sclerosis (SSc) patients have unique and persistent alteration in gastric myoelectrical activity (GMA) with acupressure to Neiguan point PC6. J Rheumatol 2005; 32: 494-501.
11. DESSEIN PH, JOFFE BI, METZ RM, MILLAR DL, LAWSON M, STANWIX AE: Autonomic dysfunction in systemic sclerosis: sympathetic overactivity and instability. Am J Med 1992; 93: 143-50.
12. MATUCCI-CERINIC M. GIACOMELLI R. PIGNONE A et al.: Nerve growth factor and neuropeptides circulating levels in systemic sclerosis (scleroderma). Ann Rheum Dis 2001; 60: 487-94.
13. BERTINOTTI L, BRACCI S, NACCI F et al.: The autonomic nervous system in systemic sclerosis. A review. Clin Rheumatol 2004; 23: 1-5.
14. McNEARNEY TA, SALLAM H, HUNNICUTT SE et al.:. Correlations of gastric myoelectrical activity (GMA) with gastrointestinal (GI) symptoms, perceived functioning, quality of life scores and gastric peptide levels in SSc, Neurogastroenterol Motil 2009; 21: 1269-77.
15. SLUKA KA, WALSH D: Transcutaneous electrical nerve stimulation: Basic science mechanisms and clinical effectiveness. J Pain 2003; 4: 109-21.
16. CAO X: Scientific bases of acupuncture analgesia. Acupunct Electrother Res 2002; 27: 1-14.
17. MELZACK R, WALL PD: Pain mechanisms, New Theory. Science 1965; 150: 971-9.
18. RADHAKRISHNAN R, SLUKA KA: Deep tissue afferents, but not cutaneous afferents, mediate transcutaneous electrical nerve stimulation-Induced antihyperalgesia. J Pain 2005; 6: 673-80.
19. NIE H, ARENDT-NIELSEN L, ANDERSEN H, GRAVEN-NIELSEN T: Temporal summation of pain evoked by mechanical stimulation in deep and superficial tissue. J Pain 2005; 6: 348-55.
20. HAN JS: Acupuncture: neuropeptide release produced by electrical stimulation of different frequencies. Trends Neurosci 2003; 26: 17-22.
21. KIM HY, HAHM DH, PYUN KH et al.: Effects of acupuncture at GV01 on experimentally induced colitis in rats: possible involvement of the opioid system. Jpn J Physiol 2005; 55: 205-10.
22. TATEWAKI M, STRICKLAND C, FUKUDA H et al.: Effects of acupuncture on vasopressin-induced emesis in conscious dogs.Am J Physiol Regul Integr Comp Physiol 2005; 288: R401-8.
23. SALLAM H, McNEARNEY TA, DOSHI D, CHEN JDZ: Electroacupuncture improves GI symptoms and physical functioning by balancing the sympathovagal activity in patients with systemic sclerosis. Dig Dis Sci 2007; 52: 1329-37.
24. MASI AT, RODNAN GP, MEDSGER TA JR. et al.: Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980; 23: 581-90.
25. CHEN JD, McCALLUM RW: Clinical applications of electrogastrography. Am J Gastroenterol 1993; 88: 1324-36.
26. CHANG, FULL-YOUNG: Electrogastrography: basic knowledge, recording processing and its clinical applications. J Gastroenterology and Hepatology 2005; 20: 502-16.
27. CHEN JD, PAN J, McCALLUM RW: Clinical significance of gastric myoelectrical dysrhythmias. Dig Dis 1995; 13: 275-90.
28. LIN X, LIANG J, REN J, MU F, ZHANG M, CHEN JD: Electrical stimulation of acupuncture points enhances gastric myoelectrical activity in humans. Am J Gastroenterol 1997; 92: 1527-30.
29. KHANNA D, HAYS RD, PARK GS et al.: Development of a preliminary scleroderma gastrointestinal tract 1.0 quality of life instrument. Arthritis Rheum 2007; 57: 1280-6.
30. KHANNA D, HAYS RD, MARANIAN P et al.: Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. Arthritis Rheum 2009; 61: 1257-63.
31. LEMBO T, NALIBOFF B, MUNAKATA J et al.: Symptoms and visceral perception in patients with pain-predominant irritable bowel syndrome. Am J Gastroenterol 94: 1320-6.
32. GROLL D, VANNER SJ, DEPEW WT et al.: The IBS-36: a new quality of life measure for irritable bowel syndrome. Am J Gastroenterol 2002; 97: 962-71.
33. KHANNA D, FURST DE, CLEMENTS PJ et al.: Relaxin Study Group. Scleroderma Clinical Trials Consortium. Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial. J Rheumatol 2005; 32: 832-40.
34. DANIELI E, PAOLO A, LORENZO B et al.: Health-related quality of life measured be the Short Form 36 (S-36) in systemic sclerosis: correlations with indexes of disease activity and severity, disability, and depressive symptoms. Clin Rheumatol 2005; 24: 48-54.
35. Del ROSSO A, BOLDRINI M, AGOSTINO D et al.: Health-related quality of life in systemic sclerosis as measured by the Short Form 36: Relationship with clinical and biologic markers. Arthritis Rheum 2004; 51: 475-81.
36. CLEMENTS PJ, LACHENBRUCH PA, SEIBOLD JR et al.: Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 1993; 20: 1892-6.
37. MEDSGER TA Jr., SILMAN AJ, STEEN VD et al.: A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 1999; 26; 2159-67.
38. MEDSGER TA Jr., BOMBARDIERI S, CZIRJAK L, SCORZA R, Della ROSSA A, BENCIVELLI W: Assessment of disease severity and prognosis. Clin Exp Rheumatol 2003; 21 (Suppl. 29): S42-46.
39. FLEISS JL: Categories. Statistical Methods and Proportions, New York, John Wiley, 2nd ed 1981, p. 218.
40. MONNIKES H, van der VOORT IR: Gastric electrical stimulation in gastroparesis: where do we stand? Dig Dis 2006; 24: 260-6.
41. CUTTS TF, LUO J, STARKEBAUM W, RASHED H, ABELL TL: Is gastric electrical stimulation superior to standard pharmacologic therapy in improving GI symptoms, healthcare resources, and long-term health care benefits?. Neurogastroenterol Motil 2005; 17: 35-43.
42. McCALLUM RW, CHEN JD, LIN Z, SCHIRMER BD, WILLIAMS RD, ROSS RA: Gastric pacing improves emptying and symptoms in patients with gastroparesis. Gastroenterology 1998; 114: 456-61.
43. HOCKING MP, VOGEL SB, SNINSKY CA: Human gastric myoelectric activity and gastric emptying following gastric surgery and with pacing. Gastroenterology 1992; 103: 1811-6.
44. ZHU H, SALLAM H, CHEN DD, CHEN JDZ: Therapeutic potential of synchronized gastric electrical stimulation for gastroparesis: enhanced gastric motility in dogs. Am J Physiol Regul Integr Comp Physiol 2007; 293: R1875-R1881.
45. AKESSON A, EKMAN R, PRYTZ H, SUNDLER F: Tissue concentrations of gastrointestinal regulatory peptides in plasma and duodenal mucosa in systemic sclerosis. Clin Exp Rheumatol 1998; 16: 141-8.
46. KASSIM SK, El TOUNY M, El GUINAIDY M, El MOGHNO MA, El MOHSEN AA: Serum nitrates and vasoactive intestinal peptide in patients with gastrointestinal reflux disease. Clinical Biochemistry 2002; 35: 641-6.
47. AKESSON A, EKMAN R: Gastrointestinal regulatory peptides in systemic sclerosis. Arthritis Rheum 1993; 36: 698-703.
48. MANETTI M, NEUMANN E, MILIA AF et al.: Severe fibrosis and increased expression of fibrogenic cytokines in the gastric wall of systemic sclerosis patients. Arthritis Rheum 2007; 56: 3442-7.
49. OVERHAUS M, MOORE BA, BARBATO JE, BEHRENDT FF, DOERING JG, BAUER AJ: Biliverdin protects against polymicrobial sepsis by modulating inflammatory mediators. Am J Physiol Gastrointest Liver Physiol 2005; 289: L1131-113.
50. PAKOZDI A, WILSON H, BLACK CM, DENTON CP: Does long term therapy with lansoprazole slow progression of oesophageal involvement in systemic sclerosis? Clin Exp Rheumatol 2009; 27 (Suppl. 54): S5-8.